作者
John JV McMurray, Milton Packer, Akshay S Desai, Jianjian Gong, Martin P Lefkowitz, Adel R Rizkala, Jean L Rouleau, Victor C Shi, Scott D Solomon, Karl Swedberg, Michael R Zile
发表日期
2014/9/11
期刊
New England Journal of Medicine
卷号
371
期号
11
页码范围
993-1004
出版商
Massachusetts Medical Society
简介
Background
We compared the angiotensin receptor–neprilysin inhibitor LCZ696 with enalapril in patients who had heart failure with a reduced ejection fraction. In previous studies, enalapril improved survival in such patients.
Methods
In this double-blind trial, we randomly assigned 8442 patients with class II, III, or IV heart failure and an ejection fraction of 40% or less to receive either LCZ696 (at a dose of 200 mg twice daily) or enalapril (at a dose of 10 mg twice daily), in addition to recommended therapy. The primary outcome was a composite of death from cardiovascular causes or hospitalization for heart failure, but the trial was designed to detect a difference in the rates of death from cardiovascular causes.
Results
The trial was stopped early, according to prespecified rules, after a median follow-up of 27 months, because the boundary for an overwhelming benefit with LCZ696 had been crossed. At the time of …
学术搜索中的文章
JJV McMurray, M Packer, AS Desai, J Gong… - New England Journal of Medicine, 2014
JJ McMurray, M Packer, SD Solomon - The New England journal of medicine, 2014
JJV McMurray, M Packer, SD Solomon - New England Journal of Medicine, 2014
JJ McMurray, M Packer, AS Desai, J Gong… - N Engl J Med, 2014